Syringe

Global Insulin Pen Market Report 2024: A $14.1 Billion Forecasted Market by 2028, Registering Compound Annual Growth Rate of 6% - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 28, 2024

The global insulin pen market was valued at $9.9 billion in 2022.

Key Points: 
  • The global insulin pen market was valued at $9.9 billion in 2022.
  • The market is expected to grow at a compound annual growth rate (CAGR) of 6.1%, reaching $14.1 billion by the end of 2028.
  • In 2022, the reusable insulin pen segment held the highest market share at about 51.5%, followed by disposable pens at 48.5%.
  • This report thoroughly examines the worldwide market size of global insulin pen delivery technology, enhancing its appeal to stakeholders and readers alike.

Compilation of quality review of documents (QRD) on stylistic matters in product information

Retrieved on: 
Sunday, March 10, 2024

29 February 2024

Key Points: 
    • 29 February 2024
      EMA/25090/2002 rev.23*
      Human Medicines Division

      Compilation of QRD decisions on stylistic matters in product information
      Issues
      Abbreviations

      Connected problems
      Subscript and superscript

      QRD Suggestions
      Acronyms must be written in their standard form; e.g.

    • Cmax, Cmax
      Abbreviations and

      Not always understood,

      Non-standard abbreviations and acronyms should be avoided, and the term should be written out in full.

    • The same applies when stating the pharmaceutical form in section 3 of the SmPC and section 4 of the labelling;
      i.e.
    • critical steps prior to administration of the product should also be included (section 5 of Annex IIIA).
    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 2/23

      Issues

      Connected problems

      QRD Suggestions

      emphasise in the labelling
      the special handling prior
      to administration of the
      product.

    • Consistency

      Inconsistencies in style are

      Once a particular style or house style has been selected, it must be used consistently throughout the text.

    • Tradename 150 mg solution for injection in pre-filled syringe
      Tradename 150 mg solution for injection in pre-filled pen

      information annexes?

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 3/23

      Issues
      Desiccant

      Connected problems

      QRD Suggestions

      For medicinal products

      The foil of blister packs containing a desiccant must be clearly labelled to show which blister pocket contains

      packaged with a desiccant

      the desiccant.

    • For bottles containing a desiccant, a similar statement should also be considered provided there

      mistake the desiccant for a

      is available space.

    • It can only be included in brackets in section 3 of the

      where can this be

      SmPC and section 4 of the labelling.

    • Direct speech should only
      be used in section 6 of the SmPC for instructions about shelf-life, storage, handling and disposal.
    • The term ?drug? though can be used in the product information annexes when it is part of a standard set of
      terms (e.g.
    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 5/23

      Issues
      Foreign terms

      Connected problems

      QRD Suggestions

      Foreign terms, particularly

      Foreign terms must be written in italics; e.g.

    • Patients can be referred to as ?he? or

      physician is often referred

      as ?she? when the medicinal product is exclusively for use by males or females.

    • if the product in question might be

      measurements are

      used by elderly patients), in brackets after the metric measures in the English text.

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 6/23

      Issues

      Connected problems

      QRD Suggestions

      product name is composed
      of MAH+INN?

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 7/23

      Issues

      Connected problems

      QRD Suggestions
      MT: English
      BG: Bulgarian
      NL: Dutch
      CZ: Czech or English at applicant?s discretion.

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 14/23

      Issues

      Connected problems

      QRD Suggestions
      considered, e.g.

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 16/23

      Issues
      Symbols: Non-Unicode

      Connected problems

      QRD Suggestions

      The use of non-Unicode

      Only Unicode symbols must be used in submitted product information annexes.

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 20/23

      Issues

      Connected problems

      Units: SI base units -

      International Standard

      litre

      base units have been
      introduced in the European
      Union with Council
      Directive 80/181/EEC of
      20.12.79 (O.J.

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 23/23

Avanos Medical, Inc. Announces Voluntary Recall in Response to Nurse Assist, LLC Sterile Water Medical Products Recall

Retrieved on: 
Thursday, February 22, 2024

These kits include Nurse Assist supplied syringes, pre-filled with sterile water, essential for inflating the retention balloon of the feeding tube.

Key Points: 
  • These kits include Nurse Assist supplied syringes, pre-filled with sterile water, essential for inflating the retention balloon of the feeding tube.
  • The Nurse Assist voluntary recall was initiated due to concerns about the potential lack of sterility assurance in these water-based products.
  • This deficiency may lead to non-sterile products, posing a risk of the water coming into contact with a patient's surgical site.
  • The pre-filled syringe is the only item in the Avanos feeding tube kit affected by the Nurse Assist recall.

Sharps Technology Planning To Collaborate With Roncadelle To Support Global Distribution And Sales Of High Quality, Innovative, Safer Drug Delivery Systems

Retrieved on: 
Friday, February 16, 2024

Sharps Technology specializes in the development and manufacturing of innovative drug delivery systems.

Key Points: 
  • Sharps Technology specializes in the development and manufacturing of innovative drug delivery systems.
  • These features protect frontline healthcare workers from life-threatening needle stick injuries and protect the public from the dangers of needle re-use.
  • Their SafeR Retractable Safety Syringe and needles offer a passive safety system with auto-disable reuse prevention features.
  • Additionally, as a Contract Development and Manufacturing Organization (CDMO), they also provide end-to-end services from design to finished products of innovative, safer medical drug delivery solutions.

INCOG BioPharma Services adds 100 million units of syringe/cartridge capacity

Retrieved on: 
Thursday, February 15, 2024

FISHERS, Ind., Feb. 15, 2024 /PRNewswire/ -- INCOG BioPharma Services, a US-based contract development and manufacturing organization (CDMO) specializing in sterile injectables, is adding a high-speed OPTIMA filling line that will provide an additional 100 million units of syringe and cartridge filling capacity.

Key Points: 
  • FISHERS, Ind., Feb. 15, 2024 /PRNewswire/ -- INCOG BioPharma Services, a US-based contract development and manufacturing organization (CDMO) specializing in sterile injectables, is adding a high-speed OPTIMA filling line that will provide an additional 100 million units of syringe and cartridge filling capacity.
  • It will complement the company's existing multi-use filling line, bringing the company's total filling capacity to 140 million units per year.
  • In addition to the new filling line, INCOG recently added automated visual inspection capabilities and will soon complete qualification of equipment to support auto-injector device assembly services.
  • The decision to increase capacity, well before current capacity limits were reached, was based on a business philosophy that prioritizes customer needs.

Medical Plastics Market Analysis Reveals Expanding Applications and Technological Advances Through 2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 12, 2024

In 2022, the global market for medical plastics was dominated by the North American region.

Key Points: 
  • In 2022, the global market for medical plastics was dominated by the North American region.
  • North America holds a 42.3% share of the global medical plastics market.
  • The base year considered for analysis is 2022, and the market estimates and forecasts are given from 2023 to 2028.
  • The scope for the medical plastics market is segmented into application and resin type.

CTLT Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Catalent, Inc. for Potential Securities Law Violations

Retrieved on: 
Wednesday, February 7, 2024

The plant is among those being acquired by Novo Nordisk in connection with the recently announced acquisition of Catalent by Novo Holdings.

Key Points: 
  • The plant is among those being acquired by Novo Nordisk in connection with the recently announced acquisition of Catalent by Novo Holdings.
  • On February 5, 2024, Catalent announced that it had agreed to be sold to Novo Holdings for $63.50 per share in cash.
  • As part of the transaction, Novo Nordisk will acquire three Catalent manufacturing facilities, including a plant located in Bloomington, Indiana.
  • As a result of the Bloomberg article, Catalent’s stock price dropped 2.27% in trading on February 6, 2024.

Kindeva Drug Delivery Launches New Analytical Services Global Business Unit

Retrieved on: 
Wednesday, January 31, 2024

Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, announced the expansion of its analytical services capabilities — launching a new global business unit offering integrated and stand-alone analytical support to the wider pharmaceutical, biopharmaceutical, and medical device sector.

Key Points: 
  • Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, announced the expansion of its analytical services capabilities — launching a new global business unit offering integrated and stand-alone analytical support to the wider pharmaceutical, biopharmaceutical, and medical device sector.
  • For more than half a century, Kindeva has developed significant knowledge, experience, and expertise working on inhaled, injectable, and transdermal drug delivery development programs and cGMP commercial supply.
  • Additionally, Kindeva has built deep expertise and capability in cGMP analytical services supporting its product development and supply partners.
  • In addition to increasing Kindeva’s global analytical footprint, Kindeva’s recently opened 32,000-square-foot state-of-the-art laboratories in Woodbury, Minnesota, will serve as the central hub for its expanded suite of stand-alone analytical services.

SyBridge Technologies to Participate in MD&M West

Retrieved on: 
Thursday, February 1, 2024

ITASCA, Ill., Feb. 1, 2024 /PRNewswire/ -- SyBridge Technologies, a global leader in design, tooling, and manufacturing, today announced that they will be participating at MD&M West to showcase its unparalleled ability to support every stage of the medical device lifecycle, from concept to product launch.

Key Points: 
  • ITASCA, Ill., Feb. 1, 2024 /PRNewswire/ -- SyBridge Technologies, a global leader in design, tooling, and manufacturing, today announced that they will be participating at MD&M West to showcase its unparalleled ability to support every stage of the medical device lifecycle, from concept to product launch.
  • Notably, SyBridge VP of Innovation, Research & Development Dr. Charlie Wood will be introducing the MD&M West keynote panel with a focus on Terrestrial Innovations in Quality Assurance for Space-Age Product.
  • MD&M West is the perfect stage to highlight how SyBridge is not just shaping the present, but propelling the industry towards a more efficient, innovative, and limitless future," says Dr. Charlie Wood, VP of Innovation, Research & Development at SyBridge Technologies.
  • MD&M West participants can visit SyBridge at booth #3943, where the company will be showcasing how it is pushing the boundaries of what is possible, ensuring exceptional precision, supporting greater manufacturing output, and helping brands reduce their overall costs.

EQS-News: SCHOTT Pharma delivers on 2023 targets and continues profitable growth trajectory

Retrieved on: 
Tuesday, January 30, 2024

“With our 2023 results, we have delivered on all our targets and have proven that SCHOTT Pharma is a highly profitable business.

Key Points: 
  • “With our 2023 results, we have delivered on all our targets and have proven that SCHOTT Pharma is a highly profitable business.
  • We will continue to benefit from key pharma trends and the overall market growth for injectable drugs”, said Almuth Steinkühler, CFO of SCHOTT Pharma.
  • In 2023, SCHOTT Pharma continued to deliver on its strategy and achieved several milestones along the pillars expansion and innovation.
  • On the innovation side, SCHOTT Pharma successfully introduced two leading innovations to the market that serve the pharma megatrends Glucagon-like peptide-1 (GLP-1) and mRNA.